NCT04464967 2021-05-12
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
NKGen Biotech, Inc.
Phase 1/2 Withdrawn
NKGen Biotech, Inc.
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Western Regional Medical Center